Literature DB >> 32235384

Upregulated Connexin 43 Induced by Loss-of-Functional S284L-Mutant α4 Subunit of Nicotinic ACh Receptor Contributes to Pathomechanisms of Autosomal Dominant Sleep-Related Hypermotor Epilepsy.

Kouji Fukuyama1, Masashi Fukuzawa2, Ruri Okubo1, Motohiro Okada1.   

Abstract

To study the pathomechanism and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy (ADSHE), this study determined functional abnormalities of glutamatergic transmission in the thalamocortical motor pathway, from the reticular thalamic nucleus (RTN), motor thalamic nuclei (MoTN) tosecondary motor cortex (M2C) associated with the S286L-mutant α4β2-nicotinic acetylcholine receptor (nAChR) and the connexin43 (Cx43) hemichannel of transgenic rats bearing the rat S286L-mutant Chrna4 gene (S286L-TG), which corresponds to the human S284L-mutant CHRNA4 gene using multiprobe microdialysis, primary cultured astrocytes and a Simple Western system. Expression of Cx43 in the M2C plasma membrane fraction of S286L-TG was upregulated compared with wild-type rats. Subchronic nicotine administration decreased Cx43 expression of wild-type, but did not affect that of S286L-TG; however, zonisamide (ZNS) decreased Cx43 in both wild-type and S286L-TG. Primary cultured astrocytes of wild-type were not affected by subchronic administration of nicotine but was decreased by ZNS. Upregulated Cx43 enhanced glutamatergic transmission during both resting and hyperexcitable stages in S286L-TG. Furthermore, activation of glutamatergic transmission associated with upregulated Cx43 reinforced the prolonged Cx43 hemichannel activation. Subchronic administration of therapeutic-relevant doses of ZNS compensated the upregulation of Cx43 and prolonged reinforced activation of Cx43 hemichannel induced by physiological hyperexcitability during the non-rapid eye movement phase of sleep. The present results support the primary pathomechanisms and secondary pathophysiology of ADSHE seizures of patients with S284L-mutation.

Entities:  

Keywords:  connexin; hemichannel; idiopathic epilepsy; microdialysis; zonisamide

Year:  2020        PMID: 32235384     DOI: 10.3390/ph13040058

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  9 in total

1.  Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

2.  Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus.

Authors:  Motohiro Okada; Kouji Fukuyama
Journal:  Biomolecules       Date:  2020-07-01

Review 3.  Astrocytic Connexin43 Channels as Candidate Targets in Epilepsy Treatment.

Authors:  Laura Walrave; Mathieu Vinken; Luc Leybaert; Ilse Smolders
Journal:  Biomolecules       Date:  2020-11-20

4.  Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor.

Authors:  Motohiro Okada; Ryusuke Matsumoto; Yoshimasa Yamamoto; Kouji Fukuyama
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

Review 5.  Astroglial Connexin43 as a Potential Target for a Mood Stabiliser.

Authors:  Motohiro Okada; Tomoka Oka; Misaki Nakamoto; Kouji Fukuyama; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

Review 6.  New Insights on the Role of Connexins and Gap Junctions Channels in Adipose Tissue and Obesity.

Authors:  Jorge Enrique González-Casanova; Samuel Durán-Agüero; Nelson Javier Caro-Fuentes; Maria Elena Gamboa-Arancibia; Tamara Bruna; Valmore Bermúdez; Diana Marcela Rojas-Gómez
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

Review 7.  Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions.

Authors:  Motohiro Okada; Yasuhiro Kawano; Kouji Fukuyama; Eishi Motomura; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

Review 8.  A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43.

Authors:  Motohiro Okada; Kouji Fukuyama; Takashi Shiroyama; Masahiko Murata
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

Review 9.  Can rodent models elucidate the pathomechanisms of genetic epilepsy?

Authors:  Motohiro Okada
Journal:  Br J Pharmacol       Date:  2021-05-12       Impact factor: 9.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.